Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02909439 · ClinicalTrials.gov registry record · Phase 4
Quality of Recovery After Reversal With Neostigmine or Sugammadex.
A Phase 4 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT02909439 is a Phase 4 study that has completed, run by Stony Brook University. The registered enrollment target is 80 participants.
The verdict
NCT02909439, a Phase 4 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.
Interventions
- DRUG Sugammadex
- DRUG Neostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02909439
The ClinicalTrials.gov registry entry for NCT02909439 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT02909439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02909439 about?
NCT02909439 is a clinical study titled "Quality of Recovery After Reversal With Neostigmine or Sugammadex.". This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.
What is the current status of trial NCT02909439?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2016-11. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02909439?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT02909439?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.